Abstract
The combination of diabetes mellitus and coronary artery disease (CAD) constitutes an aggressive disease characterized biologically by chronic inflammatory, proliferative and pro-thrombotic situation. In the “diabetic patient” the increased frequency and gravity of simultaneous myocardial infarction and the deterioration of congestive heart failure contribute to the inevitable unfavourable final result. Diabetes accelerates the natural course of atherosclerosis and involves a great number of coronary vessels with more diffuse atherosclerotic lesions. Moreover, the risks of plaque ulceration and thrombosis have been shown to be considerably higher in diabetic patients. The treatment should be also aggressive and be based on the combined treatment of CAD and the effective regulation of glucose levels. The decision of revascularization in the diabetic patient should be posed relatively earlier. The surgical choice of revascularization seems to be advantageous over the interventional, with better early and late results.
Keywords: Coronary artery disease, Diabetes mellitus, Coronary artery bypass grafting, Percutaneous transluminal coronary angioplasty, Myocardial infarction, Revascularization, percutaneous transluminal, Surgical revascularization, prothrombotic situation, lipoproteins, manifestations, triglyceride-rich, triggering mechanisms, Plaque-angiogenesis, catabolism, CABG surgery, Abciximab, ischemia, SPECT, AWESOME, worsening symptoms, BASKET-LATE, MACE, perioperatively
Current Diabetes Reviews
Title: Surgical or Interventional Revascularization in Diabetic Patients with Coronary Artery Disease?
Volume: 6 Issue: 6
Author(s): E. Apostolakis, I. Koniari, D. Velissaris and Efstratios N. Koletsis
Affiliation:
Keywords: Coronary artery disease, Diabetes mellitus, Coronary artery bypass grafting, Percutaneous transluminal coronary angioplasty, Myocardial infarction, Revascularization, percutaneous transluminal, Surgical revascularization, prothrombotic situation, lipoproteins, manifestations, triglyceride-rich, triggering mechanisms, Plaque-angiogenesis, catabolism, CABG surgery, Abciximab, ischemia, SPECT, AWESOME, worsening symptoms, BASKET-LATE, MACE, perioperatively
Abstract: The combination of diabetes mellitus and coronary artery disease (CAD) constitutes an aggressive disease characterized biologically by chronic inflammatory, proliferative and pro-thrombotic situation. In the “diabetic patient” the increased frequency and gravity of simultaneous myocardial infarction and the deterioration of congestive heart failure contribute to the inevitable unfavourable final result. Diabetes accelerates the natural course of atherosclerosis and involves a great number of coronary vessels with more diffuse atherosclerotic lesions. Moreover, the risks of plaque ulceration and thrombosis have been shown to be considerably higher in diabetic patients. The treatment should be also aggressive and be based on the combined treatment of CAD and the effective regulation of glucose levels. The decision of revascularization in the diabetic patient should be posed relatively earlier. The surgical choice of revascularization seems to be advantageous over the interventional, with better early and late results.
Export Options
About this article
Cite this article as:
Apostolakis E., Koniari I., Velissaris D. and N. Koletsis Efstratios, Surgical or Interventional Revascularization in Diabetic Patients with Coronary Artery Disease?, Current Diabetes Reviews 2010; 6 (6) . https://dx.doi.org/10.2174/157339910793499100
DOI https://dx.doi.org/10.2174/157339910793499100 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Importance of Reendothelialization After Arterial Injury
Current Pharmaceutical Design Realising Heart Regeneration
Current Tissue Engineering (Discontinued) TNFα as Therapeutic Target: New Drugs, More Applications
Current Drug Targets - Inflammation & Allergy Effects of Dietary Polyunsaturated Fatty Acids on Mitochondria
Current Pharmaceutical Design In-hospital Falls in Older Patients: The Risk Factors and The Role of Hyponatraemia
Current Aging Science Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets Prevalence of Analgesic Use and Pain in People with and without Dementia or Cognitive Impairment in Aged Care Facilities: A Systematic Review and Meta-Analysis
Current Clinical Pharmacology “Non-Classical” Indication for Provocative Testing of Growth Hormone: A Retrospective Cohort Study in Adult Patients Under Replacement Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Gold(III) Complexes in the Oncological Preclinical Arena: From Aminoderivatives to Peptidomimetics
Current Topics in Medicinal Chemistry Prediction Models and Scores in Adult Congenital Heart Disease
Current Pharmaceutical Design Patent Selections
Recent Patents on Biomarkers Ageing Mechanisms and Associated Lipid Changes
Current Vascular Pharmacology The Mechanistic Links Between Proteasome Activity, Aging and Agerelated Diseases
Current Genomics Computational Methods and Algorithms for Mass Spectrometry Based Differential Proteomics: Recent Advances, Perspectives and Open Problems
Current Proteomics Contribution of ALDH2 Polymorphism to Alcoholism-Associated Hypertension
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery SUMOylation Modulates CFTR Biogenesis: Is the Pathway Druggable?
Current Drug Targets Phytoconstituents of <i>Lantana camara</i> L.: Rekindling Hope in the Cancer Treatment
Current Bioactive Compounds MicroRNA-21 as Therapeutic Target in Cancer and Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Novel Strategies in the Treatment of Pulmonary Arterial Hypertension
Current Drug Targets Interactions of Cisplatin with non-DNA Targets and their Influence on Anticancer Activity and Drug Toxicity: The Complex World of the Platinum Complex
Current Cancer Drug Targets